Spectrum of Dyselectrolytemia Induced by Liposomal Amphotericin B In Neonates
DOI:
https://doi.org/10.51253/pafmj.v76iSUPPL-7.12278Keywords:
Amphotericin B, Anti-fungal Agents, Electrolytes, Dyselectrolytemia, Liposomes, NeonatesAbstract
Objective: To compare the spectrum of dyselectrolytemia induced after treatment by liposomal Amphotericin B (LAmB) in neonates being treated for fungal infections
Study Design: Quasi-experimental study
Place and Duration of Study: Department of Pediatrics, Combined Military Hospital Rawalpindi, Pakistan from Aug 2023 to Jan 2024
Methodology: Pre-therapy baseline investigations including Blood complete picture, Urine RE and serum electrolytes (Na, K, Ca, Mg, PO4) were sent baseline values were recorded. LAmB therapy was initiated in all patients at a dose of 4 mg/kg/day for a total of 14 days. Primary variables studied were changes in serum sodium, potassium, calcium, magnesium, phosphate, and for glycosuria before starting and after completion of therapy.
Results: When comparing the primary variables before and after LAmB treatment, mean levels of sodium were 140.77±0.99 MEq/L before therapy versus 132.16±1.05 MEq/L after therapy (p<0.001). Mean levels of potassium were 5.48±0.09 MEq/L before the start of anti-fungal therapy versus 4.61±0.13 MEq/L after therapy (p<0.001). When comparing the levels of calcium, mean levels before therapy were 2.27±0.10 mmol/l before therapy and 2.27±0.10 after therapy (p=0.859).
Conclusion: LAmB results in derangement of nearly all electrolyte parameters but effective monitoring and replacement results in successful completion of therapy in neonates and prevents morbidity and mortality.
Downloads
References
1. Weimer KE, Smith PB, Puia-Dumitrescu M, Aleem S. Invasive fungal infections in neonates: a review. Pediatr Res 2022; 91(2): 404-412. https://doi.org/10.1038/s41390-021-01842-7
2. Scott BL, Hornik CD, Zimmerman K. Pharmacokinetic, efficacy, and safety considerations for the use of antifungal drugs in the neonatal population. Expert Opin Drug Metab Toxicol 2020; 16(7): 605-616.
https://doi.org/10.1080/17425255.2020.1773793
3. Roberts JK, Stockmann C, Constance JE, Stiers J, Spigarelli MG, Ward RM, et al. Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants. Clin Pharmacokinet 2014; 53(7): 581-610. https://doi.org/10.1007/s40262-014-0147-0
4. Ramírez‐Carmona W, Fernandes GLP, Díaz‐Fabregat B, Oliveira EC, do Prado RL, Pessan JP, et al. Effectiveness of fluconazole as antifungal prophylaxis in cancer patients undergoing chemotherapy, radiotherapy, or immunotherapy: systematic review and meta‐analysis. APMIS 2023; 131(11): 668-684. https://doi.org/10.1111/apm.13324
5. Bhattacharya S, Sae-Tia S, Fries BC. Candidiasis and mechanisms of antifungal resistance. Antibiotics 2020; 9(6): 312. https://doi.org/10.3390/antibiotics9060312
6. Ben-Ami R, Kontoyiannis DP. Resistance to antifungal drugs. Infect Dis Clin North Am 2021; 35(2): 279-311.
https://doi.org/10.1016/j.idc.2021.03.003
7. Maertens J, Pagano L, Azoulay E, Warris A. Liposomal amphotericin B—the present. J Antimicrob Chemother 2022; 77(Supplement_2): ii11-ii20.
https://doi.org/10.1093/jac/dkac352
8. Hoenigl M, Lewis R, van de Veerdonk F, Verweij P, Cornely O. Liposomal amphotericin B—the future. J Antimicrob Chemother 2022; 77(Supplement_2):ii21-ii34.
https://doi.org/10.1093/jac/dkac353
9. Puertas Sanjuan A, Parramón-Teixidó CJ, Hernandez-Perez S, Frick MA, Cabañas Poy MJ. Persistent dyselectrolytemia in a neonate induced by liposomal amphotericin B. A case report. Front Pediatr 2023; 10: 1099305.
https://doi.org/10.3389/fped.2022.1099305
10. Ambreen G, Rehman A, Hussain K, Sohail M, Javed S, Shamim S, et al. Neonatal fluid and electrolytes profile effect on amphotericin B associated nephrotoxicity in neonatal tertiary care unit of Karachi-Pakistan. Expert Opin Drug Saf 2020; 19(9): 1209-1217.
https://doi.org/10.1080/14740338.2020.1781813
11. Faustino C, Pinheiro L. Lipid systems for the delivery of amphotericin B in antifungal therapy. Pharmaceutics 2020; 12(1): 29. https://doi.org/10.3390/pharmaceutics12010029
12. LaMastro V, Campbell KM, Gonzalez P, Meng‐Saccoccio T, Shukla A. Antifungal liposomes: Lipid saturation and cholesterol concentration impact interaction with fungal and mammalian cells. J Biomed Mater Res Part A 2023; 111(5): 644-659.https://doi.org/10.1002/jbm.a.37501
13. Cavassin FB, Magri MMC, Vidal JE, Carlesse FAdMC, Falci DR, Baú-Carneiro JL, et al. Effectiveness, Tolerability, and Safety of Different Amphotericin B Formulations in Invasive Fungal Infections: A Multicenter, Retrospective, Observational Study. ClinTher 2024; 46(4): 322-337.
https://doi.org/10.1016/j.clinthera.2024.01.011
14. Yokota T, Yoshikawa N, Arimori K, Ikeda R. Retrospective analysis of risk factors for liposomal amphotericin B-associated nephrotoxicity. Pharmazie 2020; 75(11): 599-601.https://doi.org/10.1691/ph.2020.0731
15. Devrim F, Çağlar İ, Acar SO, Akkuş Ş, Dinçel N, Yılmaz E, et al. Evaluation of renal effects of liposomal amphotericin B in children with malignancies with KDIGO and RIFLE criteria.Nephrol Ther 2021; 17(7): 507-511.
16. Kilpatrick R, Scarrow E, Hornik C, Greenberg RG. Neonatal invasive candidiasis: updates on clinical management and prevention. Lancet Child Adolesc Health 2022; 6(1): 60-70. https://doi.org/10.1016/s2352-4642(21)00272-8
17. Koh JW. A Case of Extremely Premature Baby with Persistent Metabolic Acidosis, Hypoglycemia and Dyselectrolytemia Induced by Liposomal Amphotericin B. Soonchunhyang Med Sci 2023; 29(2): 69-72.
18. Puertas Sanjuan A, Parramón-Teixidó CJ, Hernandez-Perez S, Frick MA, Cabañas Poy MJ. Persistent dyselectrolytemia in a neonate induced by liposomal amphotericin B. A case report. Front Pediatr 2023; 10: 1099305.
Published
Issue
Section
License
Copyright (c) 2026 Asif Rasool Mughal, Samina Tabussam, Ali Maqsood, Faqeeha Hamid, Jawad ur Rehman, Bilal Munawar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
